Publicaciones en colaboración con investigadores/as de Universitat de València (19)

2023

  1. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  3. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  4. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

2021

  1. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

  2. The role of mathematical models in immuno-oncology: Challenges and future perspectives

    Pharmaceutics, Vol. 13, Núm. 7

  3. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma

    International Journal of Pharmaceutics, Vol. 608

2019

  1. Therapeutic opportunities in neuroblastoma using nanotechnology

    Journal of Pharmacology and Experimental Therapeutics, Vol. 370, Núm. 3, pp. 625-635

2018

  1. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  2. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

  3. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2016

  1. Population pharmacokinetic model of lithium and drug compliance assessment

    European Neuropsychopharmacology, Vol. 26, Núm. 12, pp. 1868-1876

  2. Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

    European Journal of Pharmaceutical Sciences, Vol. 94, pp. 46-58

2015

  1. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

    European Journal of Pharmaceutical Sciences, Vol. 74, pp. 86-94

  2. Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients

    European Journal of Pharmaceutical Sciences, Vol. 73, pp. 57-63

2014

  1. Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 6, pp. 1620-1623

  2. Pharmacokinetics of anidulafungin during albumin dialysis

    Critical Care

2010

  1. Anti-inflammatory and antioxidant activities of Jungia paniculata

    Pharmaceutical Biology, Vol. 48, Núm. 8, pp. 897-905